# US 2024/0199660 A1 · Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199660 A1
- Document ID: US20240199660A1
- Status: Published application
- Kind: A1
- Application number: 18/433,051
- Filed: 2024-02-05
- Published: 2024-06-20
- Earliest claimed: 2017-10-09
- Assignees: Compass Pathfinder Limited
- Applicants: Compass Pathfinder Limited
- Inventors: Derek John LONDESBROUGH; Christopher BROWN; Julian Scott NORTHEN; Gillian MOORE; Hemant Kashinath PATIL; David E. NICHOLS
- Web page: https://patentgrep.com/patent/US20240199660A1

## CPC

- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- C07D 209/16: Tryptamines
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A compound having the following structure:

### Claim 30 (depends on 29)

A pharmaceutical composition comprising a compound of claim 29.

### Claim 31

Crystalline psilocybin having no single impurity greater than 1% prepared by recrystallization of psilocybin from water at a temperature not greater than about 80° C.

### Claim 32 (depends on 31)

The crystalline psilocybin of claim 31, having less than 1% psilocin.

### Claim 33 (depends on 31)

The crystalline psilocybin of claim 31, having less than 0.5% psilocin.

### Claim 34 (depends on 31)

The crystalline psilocybin of claim 31, characterized by X-ray powder diffraction (XRPD) peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1 020.

### Claim 35 (depends on 33)

The crystalline psilocybin of claim 33, further characterized by XRPD peaks at least one of 2θ4±0.1, 22.2±0.1, 24.3±0.1, or 25.7±0.1° 2θ.

### Claim 36 (depends on 31)

The crystalline psilocybin of claim 31, wherein the crystalline psilocybin has a chemical purity of greater than 97%.

### Claim 37 (depends on 31)

The crystalline psilocybin of claim 31, wherein the crystalline psilocybin has a chemical purity of greater than 98%.

### Claim 38 (depends on 31)

The crystalline psilocybin of claim 31, wherein the crystalline psilocybin has a chemical purity of greater than 99%.

### Claim 39 (depends on 31)

The crystalline psilocybin of claim 31, wherein the crystalline psilocybin has a melting point of about 2θ5° C. to about 220° C.

### Claim 40

A method for manufacturing crystalline psilocybin, the method comprising:
i) reacting psilocin with tetrabenzylpyrophosphate to form benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate;
ii) reacting the benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate with hydrogen in the presence of a catalyst to form psilocybin; and
iii) crystallizing the psilocybin from water at a temperature not greater than about 80° C. to obtain the crystalline psilocybin.

### Claim 41 (depends on 31)

The method of claim 31, wherein crystalline psilocybin is characterized by X-ray powder diffraction (XRPD) peaks at 11.5±0.1, 12.0±0 0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1 020.

### Claim 42 (depends on 41)

The method of claim 41, wherein the crystalline psilocybin is further characterized by XRPD peaks at least one of 20.4±0.1, 22.2±0.1, 24.3±0.1, or 25.7±0.1 020.

### Claim 43 (depends on 41)

The method of claim 41, wherein the crystalline psilocybin has no single impurity greater than 1%.

### Claim 44 (depends on 43)

The method of claim 43, wherein the crystalline psilocybin has less than 1% psilocin.

### Claim 45 (depends on 43)

The method of claim 43, wherein the crystalline psilocybin has less than 0.5% psilocin.

### Claim 46 (depends on 41)

The method of claim 41, wherein the crystalline psilocybin has a chemical purity of greater than 97%.

### Claim 47 (depends on 41)

The method of claim 41, wherein the crystalline psilocybin has a chemical purity of greater than 98%.

### Claim 48 (depends on 41)

The method of claim 41, wherein the crystalline psilocybin has a chemical purity of greater than 99%.

### Claim 49 (depends on 41)

The method of claim 41, wherein the psilocin is prepared by a method comprising:
i) reacting 1H-indol-4-yl acetate with oxalyl chloride and dimethylamine to form 3-([(dimethylcarbamoyl)carbonyl])-1H-indol-4-yl acetate; and
ii) reacting the 3-([(dimethylcarbamoyl)carbonyl)-1H-indol-4-yl acetate with lithium aluminium hydride to form psilocin.
